Found 6 bookmarks
Custom sorting
Stealthy Jess 🇨🇦 💜 (@AdvancedTweaker) on X
Stealthy Jess 🇨🇦 💜 (@AdvancedTweaker) on X

“As many of you know, I've been repurposing HIV antiretroviral meds to treat my LC.

My energy and baseline have been slowly, consistently improving.

For everyone still asking me about my protocol, I put it all in one spot, where I can update as I go along.

My current meds: docs.google.com/spreadsheets/d… My current supplements: docs.google.com/spreadsheets/d…

Past threads with more info and background: x.com/AdvancedTweake…

x.com/AdvancedTweake…

Enjoy and AMA :)”

#What we can do to protect ourselves#Long Covid#Treatment#Useful#anecdote#protocols#antiviral#truvada#resources#compilations#repurposed drugs#HIV#HIV drugs for Long Covid
·x.com·
Stealthy Jess 🇨🇦 💜 (@AdvancedTweaker) on X
Azelastine inhibits viropexis of SARS-CoV-2 spike pseudovirus by binding to SARS-CoV-2 entry receptor ACE2 - PubMed
Azelastine inhibits viropexis of SARS-CoV-2 spike pseudovirus by binding to SARS-CoV-2 entry receptor ACE2 - PubMed
Azelastine inhibits viropexis of SARS-CoV-2 spike pseudovirus by binding to SARS-CoV-2 entry receptor ACE2
Azelastine inhibits viropexis of SARS-CoV-2 spike pseudovirus by binding to SARS-CoV-2 entry receptor ACE2
#Azelastine nasal spray#antihistamines#antiviral#treatment#spike protein#nasal treatments#protocols#What we can do to protect ourselves#prevention tips#Astelin nasal spray#Astepro nasal spray
·pubmed.ncbi.nlm.nih.gov·
Azelastine inhibits viropexis of SARS-CoV-2 spike pseudovirus by binding to SARS-CoV-2 entry receptor ACE2 - PubMed
Frontiers | Real-world effectiveness and safety of nirmatrelvir-ritonavir (Paxlovid)-treated for COVID-19 patients with onset of more than 5 days: a retrospective cohort study
Frontiers | Real-world effectiveness and safety of nirmatrelvir-ritonavir (Paxlovid)-treated for COVID-19 patients with onset of more than 5 days: a retrospective cohort study

A study in Guangzhou, China, with 248 COVID-19 patients found that Paxlovid is effective and safe when given within 10 days of onset, reducing viral load

Effectiveness decreases after 10 days, but multiple cycles may help if the viral load remains high

#Paxlovid#antiviral#treatment#early treatment
·frontiersin.org·
Frontiers | Real-world effectiveness and safety of nirmatrelvir-ritonavir (Paxlovid)-treated for COVID-19 patients with onset of more than 5 days: a retrospective cohort study